123 related articles for article (PubMed ID: 1432610)
21. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
22. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
23. Haloperidol and reduced haloperidol in saliva and blood.
Dysken MW; Johnson SB; Holden L; Kuskowski M; Ofstehage J; Skare S; Vatassery G
J Clin Psychopharmacol; 1992 Jun; 12(3):186-90. PubMed ID: 1629385
[TBL] [Abstract][Full Text] [Related]
24. Haloperidol plasma concentrations in Taiwanese psychiatric patients.
Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH
J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974
[TBL] [Abstract][Full Text] [Related]
25. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
[TBL] [Abstract][Full Text] [Related]
26. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
27. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
Leroux JM; Elia E; Jacquet M; Pommery J; Levron JC; Bouhours P; Erb F; Sechter D
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):347-53. PubMed ID: 8208983
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
[TBL] [Abstract][Full Text] [Related]
29. Substantial rise in sparteine metabolic ratio during haloperidol treatment.
Gram LF; Debruyne D; Caillard V; Boulenger JP; Lacotte J; Moulin M; Zarifian E
Br J Clin Pharmacol; 1989 Feb; 27(2):272-5. PubMed ID: 2713222
[TBL] [Abstract][Full Text] [Related]
30. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
31. Do enzyme inducers modify haloperidol decanoate rate of release?
Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
[TBL] [Abstract][Full Text] [Related]
32. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
[TBL] [Abstract][Full Text] [Related]
33. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
35. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
[TBL] [Abstract][Full Text] [Related]
37. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
[TBL] [Abstract][Full Text] [Related]
38. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Chang WH; Lin SK; Jann MW
J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
[TBL] [Abstract][Full Text] [Related]
39. Serum haloperidol concentration and clinical response in schizophrenia.
Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
[TBL] [Abstract][Full Text] [Related]
40. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
Ulrich S; Meyer FP; Neuhof S; Knorr W
J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
